Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.078.250 €): Hefezellfabrik für die mRNA-Bioproduktion Hor01.04.2022 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Hefezellfabrik für die mRNA-Bioproduktion
Messenger RNA (mRNA) vaccines have become a game-changer in the fight against COVID-19, providing an exit strategy to the global crisis of our age. mRNA is now considered a promising biopharmaceutical for a vast array of medical applications. Currently, in vitro transcription (IVT) is the only available technology for mRNA production; however, it relies on a complex supply chain and costly purification process. Reliable large-scale IVT production is challenging and high production costs are an issue for low-income countries, and this will be even more critical for clinical mRNA applications requiring high doses. Yscript’s groundbreaking nature lies in the generation of a specific mRNA bioproduction process in yeast, integrating innovative extraction and purification processes, representing a complete shift of paradigm compared to IVT production and a revolutionary new use of yeast. Although yeast possesses a similar mature mRNA structure as humans and is recognized as safe for pharmaceutical production, mRNA bioproduction and isolation have never been attempted. Yscript will provide groundbreaking technological improvements by: i) decreasing the mRNA production supply chain; ii) increasing the purity yield of long mRNA by avoiding premature termination occurring during IVT; and iii) guarantying mRNA stability through integrated extraction-purification processes. This will ensure the generation of high-quality mRNA therapeutics, while streamlining production and reducing costs. Yscript brings together world-class expertise in molecular biology, biophysics, biotechnology, chemistry, chemical engineering, mRNA therapeutics, yeast Ty biology, bioproduction and purification processes. The project will significantly advance the current state of the art of mRNA manufacturing. Yscript will foster citizens’ well-being and health, while decreasing economic and social disparities associated with biopharmaceutical-based therapies, in which mRNA is nowadays a key element.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Centre National de la Recherche Scientifique CNRS | 267.151 € |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | 279.000 € |
| Inrae Transfert SAS | 0,00 € |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | 535.658 € |
| Instytut Chemii Bioorganicznej Polskiej Akademii Nauk | 273.310 € |
| Sartorius Bia Separations, Separacijske Tehnologije d.o.o. | 353.230 € |
| TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GmbH | 491.913 € |
| Universidade da Beira Interior | 200.826 € |
| Universidade de Aveiro | 303.974 € |
| Universite d'Orleans | 0,00 € |
Quelle: https://cordis.europa.eu/project/id/101047214
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
